ReviewComputational and structural biotechnology journal2016
Zebrafish small molecule screens: Taking the phenotypic plunge.
Review in Computational and structural biotechnology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Zebrafish swimming towards cures: a scalable NAM platform for drug discovery.Drug discovery today · 2026Review
- Insights into Cardiomyocyte Regeneration from Screening and Transcriptomics Approaches.International journal of molecular sciences · 2026Review
- In Silico Identification of Molecular Interactions of the Emerging Contaminant Octyl Methoxycinnamate (OMC) on HPT Axis: Implications for Humans and Zebrafish.Pharmaceuticals (Basel, Switzerland) · 2025Article
- FDA-approved drug repurposing in zebrafish identifies thyroid hormone and other compounds as potential antithrombotics.bioRxiv : the preprint server for biology · 2025Article
- Mapping Molecular Networks withinPharmaceuticals (Basel, Switzerland) · 2022Article
- An Overview of Zebrafish Modeling Methods in Drug Discovery and Development.Advances in experimental medicine and biology · 2022Article
- Insights Into the Biogenesis and Emerging Functions of Lipid Droplets From Unbiased Molecular Profiling Approaches.Frontiers in cell and developmental biology · 2022Review
- Specific Pathogen Free - A review of strategies in agriculture, aquaculture, and laboratory mammals and how they inform new recommendations for laboratory zebrafish.Research in veterinary science · 2021Review
- Tipping the Scales With Zebrafish to Understand Adaptive Tumor Immunity.Frontiers in cell and developmental biology · 2021Review
- A Roadmap to Gene Discoveries and Novel Therapies in Monogenic Low and High Bone Mass Disorders.Frontiers in endocrinology · 2021Review
- Zebrafish as a tool to study schizophrenia-associated copy number variants.Disease models & mechanisms · 2020Review
- Dare to Compare. Development of Atherosclerotic Lesions in Human, Mouse, and Zebrafish.Frontiers in cardiovascular medicine · 2020Review
- Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae.Frontiers in pharmacology · 2019Review
- Model organism data evolving in support of translational medicine.Lab animal · 2018Review
- Translating Knowledge Into Therapy for Acute Kidney Injury.Seminars in nephrology · 2018Review
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Target based chemical screens are a mainstay of modern drug discovery, but the effectiveness of this reductionist approach is being questioned in light of declines in pharmaceutical R & D efficiency. In recent years, phenotypic screens have gained increasing acceptance as a complementary/alternative approach to early drug discovery. We discuss the various model organisms used in phenotypic screens, with particular focus on zebrafish, which has emerged as a leading model of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.